News & Resources

Published On 15 March

Appendix 3Z – Jamie Khoo – March 2019

Appendix 3Z

Learn more
Published On 15 March

Appendix 3X – Kit Wei Lui – March 2019

Appendix 3X

Learn more
Published On 12 March

Board Changes – March 2019

Board Changes

Learn more
Published On 06 March

Cleansing Statement – March 2019

Cleaning Statement

Learn more
Published On 06 March

Appendix 3B – March 2019

Appendix 3B

Learn more
Published On 04 March

Appendix 4D – Half Yearly Report and Accounts

Appendix 4D – Half Yearly Report and Accounts

Learn more
Published On 19 February

Invitrocue Appoints Professor Arial Zeng Yi as Patient Derived Organoid Consultant

EXCERPT:  February 18, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Arial Zeng Yi as Patient Derived Organoid (PDO) Consultant. Professor Zeng is currently Principal Investigator at Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS). She is an […]

Learn more
Published On 11 February

Invitrocue creates Joint Venture with A*STAR scientist Dr. Chen Qingfeng

EXCERPT:  February 11, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the establishment of InvivoCue, a joint venture (JV) between Invitrocue and A*STAR scientist Dr. Chen Qingfeng. Invitrocue will own 70% of the Company, while Dr Chen will own 30%. The JV will supply humanised immune system […]

Learn more
Published On 01 February

Quarterly Appendix 4C and Business updates

Quarterly Appendix 4C and Business updates

Learn more
Published On 23 January

IVQ technology development agreement with SIBCB on breast cancer.

EXCERPT: January 23, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the signing of a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences, for the laboratory culture and development of new breast cancer models for Invitrocue’s proprietary Onco-PDO® […]

Learn more